Investors
Breaking News:
Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis. Learn more at www.abivax.com/press-releases/
Share Profile
Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.
- ISIN code: FR0012333284
- Symbol: ABVX
- ICB Classification: Healthcare 4000/ Biotechnology 4573
- Market: Euronext Paris-Compartment B
- Type of Listing: continuous
- Number of shares: 16,692,268 as of July 30, 2021
- Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
- Eligible to French PEA PME
